WO2014174388A1 - Compositions pharmaceutiques à libération modifiée de méthylphénidate ou de ses sels - Google Patents

Compositions pharmaceutiques à libération modifiée de méthylphénidate ou de ses sels Download PDF

Info

Publication number
WO2014174388A1
WO2014174388A1 PCT/IB2014/060084 IB2014060084W WO2014174388A1 WO 2014174388 A1 WO2014174388 A1 WO 2014174388A1 IB 2014060084 W IB2014060084 W IB 2014060084W WO 2014174388 A1 WO2014174388 A1 WO 2014174388A1
Authority
WO
WIPO (PCT)
Prior art keywords
methylphenidate
release component
prepared
salts
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2014/060084
Other languages
English (en)
Inventor
Girish Kumar Jain
Rahul Sudhakar Dabre
Jitendrakumar CHORDIYA
Inderjeetsingh Huda
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Priority claimed from IN1245MU2013 external-priority patent/IN2013MU01245A/en
Priority claimed from IN1248MU2013 external-priority patent/IN2013MU01248A/en
Priority claimed from IN1244MU2013 external-priority patent/IN2013MU01244A/en
Priority claimed from IN1246MU2013 external-priority patent/IN2013MU01246A/en
Priority claimed from IN1241MU2013 external-priority patent/IN2013MU01241A/en
Priority claimed from IN1250MU2013 external-priority patent/IN2013MU01250A/en
Priority claimed from IN1249MU2013 external-priority patent/IN2013MU01249A/en
Priority claimed from IN1240MU2013 external-priority patent/IN2013MU01240A/en
Priority claimed from IN1247MU2013 external-priority patent/IN2013MU01247A/en
Priority claimed from IN1242MU2013 external-priority patent/IN2013MU01242A/en
Publication of WO2014174388A1 publication Critical patent/WO2014174388A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Definitions

  • the present invention relates to modified release pharmaceutical compositions of methylphenidate or salts thereof.
  • the present invention relates to a modified release pharmaceutical compositions comprising at least one immediate release and at least one extended release component of methylphenidate or salts thereof.
  • the composition may provide extended and specific release of methylphenidate or salts thereof to achieve therapeutically effective plasma concentration over a period of 12 hours to treat attention deficit disorders when administered to a patient in need thereof.
  • the invention also includes process of preparing such composition.
  • Methylphenidate Hydrochloride a scheduled II controlled substance, is currently marketed as a mild central nervous system (CNS) stimulant and the drug of choice for treatment of Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD) in children.
  • CNS central nervous system
  • ADD Attention Deficit Disorder
  • ADHD Attention Deficit Hyperactivity Disorder
  • the drug is well absorbed throughout the gastrointestinal tract. However, it has an extremely short half-life, which necessitates a multi-dose treatment regimen for conventional (immediate release) dosage forms such as currently available 5, 10, and 20 mg tablets. Due to high C max , oral administration of 10 and 20 mg Ritalin ® is reported to result in notable side effects such as anorexia, weight loss, dizziness, etc.
  • methylphenidate requires the hyperactive children to be dosed in school thus causing hardship to school authorities as well as parents.
  • the drawback of methylphenidate is that it also produces a euphoric effect when administered intravenously or through inhalation, thus presenting a high potential for substance abuse.
  • Sustained release formulations for once-a-day dosing such as 20 mg Ritalin tablets currently available from Novartis and Geneva (generic version), were developed with the objective of providing efficacy for 8 hours, thereby improving compliance and reducing the incidence of diversion.
  • the sustained release formulations exhibit a slower onset of action/efficacy compared to the immediate release dosage forms.
  • Osmotic drug delivery based one-a day oral formulation of methylphenidate HCI is also available.
  • the dosage form contains a drug overcoat that is designed to deliver a portion of the dose for rapid onset of action and deliver the remainder of the dose in a controlled manner for about 10 hours.
  • U.S. Patent No. 5,908,850 discloses a sustained release dosage form containing d- threo-methylphenidate (commonly known as dexmethylphenidate) or pharmaceutically acceptable salts thereof thus minimizing hyperactivity and side effects.
  • U.S. Patent No. 6,344,215 discloses a modified release dosage methylphenidate capsule comprising immediate and extended release beads, each prepared by layering over the core particles.
  • methylphenidate know in the art are complicated dosage forms. Manufacturing cost of such dosage forms is expected to be very high and hence resulting in a high cost of treatment. Thus, there exist a dire need to develop modified release dosage forms of methylphenidate with moderate cost of goods and having not only a rapid onset of action but also with a significantly longer duration of action.
  • the present inventors have surprisingly found that it is possible to achieve therapeutically efficacious plasma concentrations with rapid onset of action and maintained it over a 12-hour period, thus eliminating the need to dose children in the school.
  • These objectives can be achieved by devising a new modified release composition of methylphenidate containing both immediate and extended release components of methylphenidate, such that immediate release component of the composition is not in the form of core particles coated with layer of methylphenidate.
  • the composition is simple and economical to manufacture and also involve less number of manufacturing steps.
  • a modified release pharmaceutical composition comprising at least one immediate release and at least one extended release component comprising methylphenidate or salts thereof, wherein the extended release component is not in the form of core particles coated with layer of methylphenidate.
  • a modified release pharmaceutical composition comprising at least one immediate release and at least one extended release component comprising methylphenidate or salts thereof, wherein the immediate release component is not in the form of core particles coated with layer of methylphenidate.
  • a modified release pharmaceutical composition comprising at least one immediate release and at least one extended release component comprising methylphenidate or salts thereof, wherein the immediate release component and the extended release component is not in the form of core particles coated with layer of methylphenidate.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of a mixture of methylphenidate and one or more pharmaceutically acceptable excipients.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of a mixture of methylphenidate and one or more pharmaceutically acceptable excipients and the extended release component comprises core particles coated with one or more layers of methylphenidate, which is further coated with one or more rate controlling substances.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of mixture of methylphenidate and one or more pharmaceutically acceptable excipients and the extended release component comprises matrix of methylphenidate, and one or more rate controlling substances.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of granules comprising methylphenidate or salts thereof and one or more pharmaceutically acceptable excipients.
  • a modified release pharmaceutical composition of methylphenidate or salt thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of granules comprising methylphenidate and one or more pharmaceutically acceptable excipients and the extended release component comprises core particles coated with one or more layers of methylphenidate, which is further coated with one or more rate controlling substances.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of granules comprising methylphenidate and one or more pharmaceutically acceptable excipients and the extended release component comprises matrix of methylphenidate, and one or more rate controlling substances.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of one or more mini-tablets.
  • a modified release pharmaceutical composition of methylphenidate or salt thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of one or more mini-tablets and the extended release component comprises core particles coated with one or more layers of methylphenidate, which is further coated with one or more rate controlling substances.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of one or more mini-tablets comprising methylphenidate and one or more pharmaceutically acceptable excipients and the extended release component comprises matrix of methylphenidate, and one or more rate controlling substances.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of extrudates comprising methylphenidate or salts thereof and one or more pharmaceutically acceptable excipients.
  • a modified release pharmaceutical composition of methylphenidate or salt thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of extrudates and the extended release component comprises core particles coated with one or more layers of methylphenidate, which is further coated with one or more rate controlling substances.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release component is in the form of extrudates comprising methylphenidate and one or more pharmaceutically acceptable excipients and the extended release component comprises matrix of methylphenidate, and one or more rate controlling substances.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein both the immediate release and extended release components are in the form of extrudates comprising methylphenidate and one or more pharmaceutically acceptable excipients.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, wherein the immediate release and extended release components of the composition are in the form of tablets, mini-tablets, granules, pellets, spheroids, beads, or mixtures thereof.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, characterized in that the composition retains at least 90% w/w of the potency of methylphenidate or salts thereof when stored at 40°C and 60% relative humidity for 3 months.
  • a modified release pharmaceutical composition of methylphenidate or salts thereof comprising at least one immediate release and at least one extended release component of methylphenidate, characterized in that the composition is bioequivalent to the formulation of methylphenidate marketed under the trade name Metadate CD ® .
  • the immediate release granules as disclosed in the present invention can be prepared by wet granulation, dry granulation or slugging.
  • step (b) granulating the mixture prepared in step (a) to form immediate release component in the form of granules;
  • step (d) granulating the mixture prepared in step (c) to form matrix type extended release component
  • step (e) filling the immediate release component prepared in step (a) and the extended release component prepared in step (d) in a capsule.
  • step (e) filling the immediate release component prepared in step (a) and the extended release component prepared in step (d) in a capsule.
  • step (a) mixing methylphenidate or salts thereof with one or more pharmaceutically acceptable excipients to form a mixture;
  • step (b) granulating the mixture prepared in step (a) followed by compression to form immediate release component in the form of mini-tablets;
  • step (f) filling the immediate release component prepared in step (b) and the extended release component prepared in step (e) in a capsule.
  • step (b) extruding the mixture or molten mass obtained in step (a) to obtain cylindrical extrudates having desired length and diameter to form immediate release components in the form of extrudates;
  • step (b) granulating the mixture prepared in step (a) followed by compression to form immediate release component in the form of mini-tablets;
  • step (d) granulating the mixture prepared in step (c) to form matrix type extended release component
  • step (e) filling the immediate release component prepared in step (b) and the extended release component prepared in step (d) in a capsule.
  • step (b) extruding the mixture or molten mass obtained in step (a) to obtain cylindrical extrudates having desired length and diameter to form immediate release components in the form of extrudates;
  • step (e) granulating the mixture prepared in step (d) to form matrix type extended release components; or extruding the molten mass obtained in step (d) to obtain extended release components in the form of cylindrical extrudates having desired length and diameter;
  • step (f) optionally spheronizing the extrudates prepared in step (e) to form extended release components in the form of pellets
  • step (g) filling the immediate release components prepared in step (b) or (c) and the extended release components prepared in step (e) or (f) in a capsule.
  • a method of treating ADD or ADHD by administering the patient in need thereof the modified release pharmaceutical composition of methylphenidate or salts thereof as substantially described throughout the specification.
  • the present invention relates to a novel modified release composition
  • a novel modified release composition comprising one or more immediate release components and one or more extended release components of methylphenidate or salts thereof, wherein the immediate release and/or the extended release components are not in the form of core particles coated with layer of methylphenidate.
  • the immediate release components are present in the form of methylphenidate and excipient admixture, granules, mini-tablets, extrudates or mixtures thereof and the extended release components are present in the form of core particles coated with one or more layers of methylphenidate, which is further coated with one or more rate controlling substances, matrix of methylphenidate and one or more rate controlling substances, or extrudates comprising methylphenidate and one or more pharmaceutically acceptable excipients or mixtures thereof.
  • the immediate release component in the composition of the present invention is in the form of mixture of methylphenidate or salts thereof and one or more pharmaceutically acceptable excipients, granules, mini-tablet or extrudates comprising methylphenidate or salts thereof and one or more pharmaceutically acceptable excipients and the extended release component comprises matrix of methylphenidate or salts thereof and one or more release controlling substances.
  • Such compositions may provide rapid onset of action as well as a significantly longer duration of action.
  • the composition also involves simple and economical manufacturing process.
  • the modified release pharmaceutical composition comprises of at least one immediate release and at least one extended release components comprising methylphenidate or salts thereof, wherein the immediate release component and/or the extended release component is not in the form of core particles coated with layer of methylphenidate.
  • the modified release composition of the present invention is bioequivalent to formulation of methylphenidate marketed under the trade name Metadate CD ®
  • the modified release unit dosage form of the present invention retains at least 90% w/w of the potency of methylphenidate or salts thereof when stored at 25°C and 40% relative humidity or at 40°C and 25% relative humidity for 3 months.
  • the modified release unit dosage form of the present invention is characterized in that it provides therapeutically effective plasma concentration of methylphenidate or salts thereof over a period of 12 hours.
  • the granules as disclosed in the present invention can be prepared by the methods known to those skilled in the art such as wet granulation, dry granulation or slugging.
  • component used throughout the specification refers to dry blend or mixture (e.g. powder), mini-tablet, tablet, pellet, bead or granule prepared by standard methods known to the person skilled in the art, including but not limited to compression, granulation, spray coating, and extrusion/spheronization.
  • methylphenidate used throughout the specification refers to not only methylphenidate per se, but also its other pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof.
  • modified release used throughout the specification shall apply to dosage forms, matrices, particles, coatings, portions thereof, or compositions that alter the release of an active ingredient in any manner.
  • Types of modified release include controlled, prolonged, sustained, extended, delayed, and the likes.
  • matrix used throughout the specification refers to the dispersion of drug within one or more release modifying substances and optionally one or more pharmaceutical excipients, or mixture thereof.
  • plastically deformable mass used throughout the specification refers to the mass capable of passing through extruder or perforated mesh.
  • extrudates refers to a type of physical form (e.g. particles, pellets, beads) obtained by extruding the plastically deformable (moistened or molten) mass through extruder or perforated mesh.
  • a typical method of preparing the extrudates involves a step of heating a mixture of drug along with suitable vehicle (e.g. water) under mechanical pressure in a cooker extruder.
  • suitable vehicle e.g. water
  • An alternate method is extruding the molten mixture of drug-polymer through an extruder.
  • the immediate release component of the present invention is in the form of granules comprising methylphenidate and one or more pharmaceutically acceptable excipients. In another preferred embodiment, the immediate release component of the present invention is in the form of a blend of methylphenidate and one or more pharmaceutically acceptable excipients.
  • the immediate release component of the present invention is in the form of one or more mini-tablets comprising of methylphenidate or salts thereof and one or more pharmaceutically acceptable excipients.
  • the immediate release component comprises plurality of cores prepared by processing, particularly compressing the pharmaceutically acceptable excipients to form mini-tablets comprising methylphenidate or salts thereof.
  • the immediate release component of the present invention is in the form of mini-tablets of methylphenidate and one or more pharmaceutically acceptable excipients.
  • Polymers suitable for preparing extrudates of the present invention include, but not limited to, one or more water-soluble, water-insoluble or water-swellable thermoplastic polymers.
  • the water soluble polymers that can be used, according to the present invention comprises of homopolymers and co-polymers of N-vinyl lactams, especially homopolymers and co-polymers of N-vinyl pyrrolidone, e.g., polyvinylpyrrolidone (PVP), co-polymers of PVP and vinyl acetate, co-polymers of N-vinyl pyrrolidone and vinyl acetate or vinyl propionate, dextrins such as grades of maltodextrin, cellulose esters and cellulose ethers, high molecular polyalkylene oxides, such as polyethylene oxide and polypropylene oxide, and co-polymers of ethylene oxide and propylene oxide.
  • PVP polyvinylpyrrolidone
  • dextrins such as grades of maltodextrin
  • cellulose esters and cellulose ethers high molecular polyalkylene oxides, such as polyethylene oxide and polypropylene oxide
  • the water soluble polymer is preferably present in the range wherein the ratio of drug to polymer is 1 :0.5 to 1 :6.
  • the water insoluble polymers that can be used, according to the present invention comprises of acrylic copolymers, e.g., Eudragit E100 or Eudragit EPO; Eudragit L30D-55, Eudragit FS30D, Eudragit RL30D, Eudragit RS30D, Eudragit NE30D, Acryl-Eze (Colorcon Co.); polyvinylacetate, for example, Kollicoat SR 30D (BASF Co.); cellulose derivatives such as ethylcellulose, cellulose acetate, e.g., Surelease (Colorcon Co.), Aquacoat ECD and Aquacoat CPD (FMC Co.).
  • the most preferred water insoluble polymer is Eudragit E100.
  • the water insoluble polymer is preferably present in the range wherein the ratio of drug to polymer is 1 :1 to 1 :6. Additionally, the water insoluble polymer may be combined with organic acids, such as from citric acid, tartaric acid, glycolic acid, etc.
  • extrudates as disclosed in the present invention can also be prepared by various other methods known to those skilled in the art such as extrusion.
  • the extended release components are in the form of beads.
  • the beads may be matrix type or of inert core coated with one or more drug layers and optionally coated with one or more barrier coating.
  • the extended release component of the present invention may be comprised of an inert particle such as a commercially available non-pareil sugar sphere.
  • Methyl phenidate is layered on the sugar spheres from an aqueous solution of the drug and a binder such as polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • the drug layered beads are provided with up to 4%, preferably up to 2% w/w barrier coat using a film-former, such as hydroxypropylmethylcellulose (HPMC) (e.g., Opadry Clear).
  • HPMC hydroxypropylmethylcellulose
  • Extended release components can be prepared by coating drug coated/barrier coated beads as mentioned above with a solution or an aqueous dispersion of a dissolution rate controlling polymer thereby forming an extended release membrane coating on the IR bead.
  • the release controlling substances which can be used may be selected from the group consisting of hydrophilic agents (e.g. water-soluble polymers), lipophilic agents (water-insoluble polymers) and inert matrix agents, wherein the hydrophilic agents are selected from the group of pharmaceutical excipients which generate a gel in contact with water, including cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose and the like; noncellulose polysaccharides such as galactomannanes, guar gum, carob gum, gum arabicum, alginates, pectins, and the like; polyvinylpyrrolidone; polyvinylacetate polymers and copolymers; acrylic acid polymers and copolymers, polyethylene oxide and mixtures thereof; the lipophilic agents are selected from the group consisting of waxes such as white wax, bees wax, carnauba wax and the like; fatty acids and alcohols such as stearic acid
  • thermoplastic polymers which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and mixtures thereof.
  • rate controlling substances include, but are not limited to, ethylcellulose (e.g., Aquacoat ® ECD-30), neutral copolymers based on ethylacrylate and methylmethacrylate, and copolymers of acrylic and methacrylic acid esters having quaternary ammonium groups.
  • the membrane coated beads are also typically seal coated with HPMC to produce extended release beads.
  • the immediate and/or extended release component in accordance with the invention are provided with up to 4%, preferably up to 2% w/w barrier coat using a film-former, such as hydroxypropylmethylcellulose (HPMC) (e.g., Opadry Clear).
  • HPMC hydroxypropylmethylcellulose
  • the immediate release and extended release components are filled into hard gelatin capsules at predetermined ratios to produce modified release capsule. Ratios of immediate release and extended release components found to provide desirable release profiles ranges from about 10:90 to 50:50, preferably from 20:80 to 40:60, and most preferably at a ratio of 30:70.
  • the amount of methylphenidate in the composition can be varied widely.
  • a typical dose is expected to be from about 10 to 60 mg of methylphenidate.
  • Immediate release components typically will account for about 20 to 40% of the dose.
  • the methylphenidate content in the extended release components may range from 5 to 20% w/w.
  • the rate controlling substance in the methylphenidate extended release component may vary from 5 to 25%, preferably from 5 to 20% and more preferably from 5 to 10% by weight based on the total weight of the extended release component, depending on the rate controlling substance and pharmaceutical excipients selected.
  • the thickness of the membrane layer or the amount or type of rate controlling substance selected depends on the desired release profile, and is optimized for achieving a desired in vitro release profile, which is predicted based on the in vitro/in vivo correlations and efficacy study results.
  • the release profile provides an immediate bolus of drug and extended release of the drug at a relatively constant rate for an extended period of time (over 12 hours or more).
  • composition according to the present invention may comprise extended release component, preferably in the form of pellets, which provides only an extended release profile and granules comprising methylphenidate with one or more pharmaceutical excipients exhibiting immediate release.
  • extended release component preferably in the form of pellets, which provides only an extended release profile and granules comprising methylphenidate with one or more pharmaceutical excipients exhibiting immediate release.
  • the composition according to the present invention may comprise one bead population, which provides only an extended release profile and a blend of methylphenidate with one or more pharmaceutical excipients exhibiting immediate release.
  • the modified release composition of the present invention can be prepared by methods known to the person skilled in the art.
  • the process of manufacturing a modified release methylphenidate composition comprises the steps of:
  • step (b) granulating the mixture prepared in step (a) to form immediate release component in the form of granules;
  • step (d) granulating the mixture prepared in step (c) to form extended release component
  • step (e) filling the immediate release component prepared in step (a) and the extended release component prepared in step (d) in a capsule.
  • the modified release composition of the present invention can be prepared by methods known to the person skilled in the art.
  • the process of manufacturing a modified release methylphenidate composition comprises the steps of:
  • step (e) filling the immediate release component prepared in step (a) and the extended release component prepared in step (a) in a capsule.
  • step (e) filling the immediate release component prepared in step (a) and the extended release component prepared in step (d) in a capsule.
  • the process for preparation of a modified release capsule comprises steps of:
  • step (b) granulating the mixture prepared in step (a) followed by compression to form immediate release component in the form of mini-tablets;
  • step (e) coating the methylphenidate layered particles with one or more layers comprising one or more rate controlling substances to form extended release component; and (f) filling the immediate release component prepared in step (b) and the extended release component prepared in step (e) in a capsule.
  • step (b) extruding the mixture obtained in step (a) to obtain cylindrical extrudates having desired length and diameter to form immediate release components in the form of extrudates;
  • step (g) filling the immediate release component prepared in step (b) or (c) and extended release component prepared in step (f) in a capsule.
  • the process of manufacturing a modified release methylphenidate composition comprises the steps of:
  • step (b) granulating the mixture prepared in step (a) followed by compression to form immediate release component in the form of mini-tablets;
  • step (d) granulating the mixture prepared in step (c) to form matrix type extended release component; (e) filling the immediate release component prepared in step (a) and the extended release component prepared in step (d) in a capsule.
  • step (b) extruding the mixture or molten mass obtained in step (a) to obtain cylindrical extrudates having desired length and diameter to form immediate release components in the form of extrudates;
  • step (e) granulating the mixture prepared in step (d) to form matrix type extended release components
  • step (d) or extruding the molten mass obtained in step (d) to obtain extended release components in the form of cylindrical extrudates having desired length and diameter;
  • step (f) optionally spheronizing the extrudates prepared in step (e) to form extended release components in the form of pellets
  • step (g) filling the immediate release components prepared in step (b) or (c) and the extended release components prepared in step (e) or (f) in a capsule.
  • Binder for preparing extended release component of methylphenidate may be selected from water soluble, alcohol soluble or acetone/water soluble binders are used. Binders such as polyvinylpyrrolidone (PVP), polyethylene oxide, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), polysaccharides such as dextran, corn starch may be used at concentrations of 0.5 to 5% w/w. Methylphenidate may be present in the extended release component up to 55% w/w, preferably up to about 40% w/w, and most preferably up to about 20% w/w.
  • PVP polyvinylpyrrolidone
  • HPMC hydroxypropyl methylcellulose
  • HPC hydroxypropyl cellulose
  • Methylphenidate may be present in the extended release component up to 55% w/w, preferably up to about 40% w/w, and most preferably up to about 20% w/w.
  • the modified release composition of methylphenidate or salts thereof may be developed in the form a capsule, a tablet, a caplet and a mini-tablet.
  • the dosage form is in the form of a capsule.
  • the modified release composition in accordance of the present invention is in the form of a hard gelatin capsule filled with granules comprising methylphenidate or salts thereof and one or more pharmaceutically acceptable excipients, and plurality of pellets comprising matrix of methylphenidate or salts thereof and one or more rate controlling substances.
  • pharmaceutically acceptable excipients includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering an active pharmaceutical ingredient. Each excipient should be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Excipients include diluents, binders, disintegrants, glidants, lubricants, flavoring, and others.
  • composition of the present invention may comprise one or more pharmaceutically acceptable excipients selected from, but not limited to, diluent, binder, disintegrant, glidant, lubricant, stabilizing agent, and flavoring agents.
  • Diluents increase the bulk of a solid pharmaceutical composition.
  • Exemplary diluents for solid compositions include, but are not limited to, microcrystalline cellulose, microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates, potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc.
  • Solid pharmaceutical compositions that are compressed may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
  • binders for solid pharmaceutical compositions include, but are not limited to, acacia, alginic acid, carbomer, carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, pregelatinized starch, sodium alginate and starch.
  • Disintegrants increase the dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach, for example.
  • Exemplary disintegrants include, but are not limited to, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate and starch.
  • Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing.
  • exemplary excipients that may function as glidants include, but not limited to, colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.
  • a lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye.
  • exemplary lubricants include, but are not limited to, magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
  • the present invention further provides a method of treating a method of treating ADD or ADHD by administering the patient in need thereof the modified release pharmaceutical composition of methylphenidate or salts thereof as substantially described throughout the specification.
  • a mixture of Methyl phenidate and Microcrystalline Cellulose was blended in a rotary mixer granulator. The blend was granulated with water in a rotary mixer granulator. The granules were dried and sifted through sieve of suitable mesh size.
  • a mixture of Methylphenidate, Polyvinylpyrrolidone, Hypromellose K4M CR and Hypromellose K15M CR was granulated with water in rotary mixer granulator. The mass was extruded through 1 .0mm bore size. The resulting extrudates were then spheronized at optimum speed to form pellets/extrudates. The pellets were then seal coated and dried. The granules and pellets were filled in size ⁇ ' hard gelatin capsules.
  • Methylphenidate and Microcrystalline Cellulose were mixed in a double cone blender to form powder blend.
  • a solution of Methylphenidate and Polyvinylpyrrolidone was sprayed on sugar spheres using fluid bed coater.
  • the drug loaded pellets were further seal coated using opadry clear in fluid bed coater.
  • the seal coated Pellets are further coated using ethyl cellulose and dibutyl sebacetate based coating in fluid bed coater to form pellets.
  • the powder blend and pellets were filled in size ⁇ ' hard gelatin capsules.
  • a mixture of Methyl phenidate and Microcrystalline Cellulose was blended in a rotary mixer granulator.
  • the blend was granulated with water in a rotary mixer granulator.
  • the granules were dried and sifted through sieve of suitable mesh size.
  • a solution of Methyl phenidate and Polyvinylpyrrolidone was sprayed on sugar spheres using fluid bed coater.
  • the drug loaded pellets were further seal coated using opadry clear in fluid bed coater.
  • the seal coated Pellets are further coated using ethyl cellulose and dibutyl sebacetate based coating in fluid bed coater to form pellets.
  • the granules and pellets were filled in size ⁇ ' hard gelatin capsules.
  • a mixture of Methylphenidate, Lactose monohydrate and Microcrystalline Cellulose was blended in a rotary mixer granulator.
  • the blend was granulated with water in a rotary mixer granulator.
  • the granules were dried and sifted through sieve of suitable mesh size and compressed to form mini-tablets.
  • a solution of Methylphenidate and Polyvinylpyrrolidone was sprayed on sugar spheres using fluid bed coater.
  • the drug loaded pellets were further seal coated using opadry clear in fluid bed coater.
  • the seal coated Pellets are further coated using ethyl cellulose and dibutyl sebacetate based coating in fluid bed coater to form pellets.
  • the mini-tablets and pellets were filled in size ⁇ ' hard gelatin capsules.
  • a mixture of Methylphenidate, Lactose monohydrate and Microcrystalline Cellulose was blended in a rotary mixer granulator. The blend was granulated with water in a rotary mixer granulator. The granules were dried and sifted through sieve of suitable mesh size and compressed to form mini-tablets.
  • a mixture of Methylphenidate, Polyvinylpyrrolidone, Hypromellose K4M CR and Hypromellose K15M CR was granulated with water in rotary mixer granulator. The mass was extruded through 1 .0mm bore size. The resulting extrudates were then spheronized at optimum speed to form pellets/extrudates. The pellets were then seal coated and dried. The mini-tablets and pellets were filled in size ⁇ ' hard gelatin capsules.
  • a mixture of Methyl phenidate and Microcrystalline Cellulose was blended in a rotary mixer granulator. The blend was blended with water and the wet mass was extruded through 1 .0mm bore size, followed by spheronization at optimum speed to from extrudates. The extrudates were dried and sifted through sieve of suitable mesh size.
  • a mixture of Methylphenidate, Polyvinylpyrrolidone, Hypromellose K4M CR and Hypromellose K15M CR was granulated with water in rotary mixer granulator. The mass was extruded through 1 .0mm bore size. The resulting extrudates were then spheronized at optimum speed to form pellets/extrudates. The pellets were then seal coated and dried. The extrudates and pellets were filled in size ⁇ ' hard gelatin capsules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques à libération modifiée de méthylphénidate ou de ses sels. En particulier, la présente invention concerne des compositions pharmaceutiques à libération modifiée comprenant au moins un composant à libération immédiate et au moins un composant à libération prolongée de méthylphénidate ou de ses sels. La composition peut fournir une libération prolongée et spécifique de méthylphénidate ou de ses sels pour obtenir une concentration plasmatique efficace sur le plan thérapeutique sur une période de 12 heures pour traiter des troubles de l'attention lorsqu'elle est administrée à un patient qui en a besoin. L'invention comprend en outre un procédé de préparation d'une telle composition.
PCT/IB2014/060084 2013-03-29 2014-03-24 Compositions pharmaceutiques à libération modifiée de méthylphénidate ou de ses sels WO2014174388A1 (fr)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
IN1241/MUM/2013 2013-03-29
IN1244/MUM/2013 2013-03-29
IN1248/MUM/2013 2013-03-29
IN1245/MUM/2013 2013-03-29
IN1247/MUM/2013 2013-03-29
IN1246/MUM/2013 2013-03-29
IN1240/MUM/2013 2013-03-29
IN1250/MUM/2013 2013-03-29
IN1242/MUM/2013 2013-03-29
IN1249/MUM/2013 2013-03-29
IN1245MU2013 IN2013MU01245A (fr) 2013-03-29 2014-03-24
IN1248MU2013 IN2013MU01248A (fr) 2013-03-29 2014-03-24
IN1244MU2013 IN2013MU01244A (fr) 2013-03-29 2014-03-24
IN1246MU2013 IN2013MU01246A (fr) 2013-03-29 2014-03-24
IN1241MU2013 IN2013MU01241A (fr) 2013-03-29 2014-03-24
IN1250MU2013 IN2013MU01250A (fr) 2013-03-29 2014-03-24
IN1249MU2013 IN2013MU01249A (fr) 2013-03-29 2014-03-24
IN1240MU2013 IN2013MU01240A (fr) 2013-03-29 2014-03-24
IN1247MU2013 IN2013MU01247A (fr) 2013-03-29 2014-03-24
IN1242MU2013 IN2013MU01242A (fr) 2013-03-29 2014-03-24

Publications (1)

Publication Number Publication Date
WO2014174388A1 true WO2014174388A1 (fr) 2014-10-30

Family

ID=50543268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/060084 WO2014174388A1 (fr) 2013-03-29 2014-03-24 Compositions pharmaceutiques à libération modifiée de méthylphénidate ou de ses sels

Country Status (1)

Country Link
WO (1) WO2014174388A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
WO1999062496A1 (fr) * 1998-06-03 1999-12-09 Alza Corporation Procedes et dispositifs servant a maintenir un effet therapeutique prolonge
WO2002000213A1 (fr) * 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20040156896A1 (en) * 2002-12-09 2004-08-12 Manesh Dixit Oral controlled release dosage form
US20120207824A1 (en) * 2011-02-15 2012-08-16 Tris Pharma, Inc. Orally effective methylphenidate extended release powder and aqueous suspension product

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
WO1999062496A1 (fr) * 1998-06-03 1999-12-09 Alza Corporation Procedes et dispositifs servant a maintenir un effet therapeutique prolonge
WO2002000213A1 (fr) * 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20040156896A1 (en) * 2002-12-09 2004-08-12 Manesh Dixit Oral controlled release dosage form
US20120207824A1 (en) * 2011-02-15 2012-08-16 Tris Pharma, Inc. Orally effective methylphenidate extended release powder and aqueous suspension product

Similar Documents

Publication Publication Date Title
AU2008213744B2 (en) A dosage form containing two or more active pharmaceutical ingredients in different physical forms
US20220062204A1 (en) Methods and compositions for the treatment of seizure-related disorders
JP6976946B2 (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
US20110218216A1 (en) Extended release pharmaceutical composition of donepezil
JP2013545762A (ja) ラコサミドの１日１回投与用製剤
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
JP2017532363A (ja) 特に注意欠陥障害の治療のための方法および組成物
US20140004189A1 (en) Modified release pharmaceutical compositions memantine
WO2011037976A2 (fr) Formulations pharmaceutiques de pramipexole
US20120003307A1 (en) Levetiracetam controlled release composition
MXPA06008854A (es) Mini tabletas de clorhidrato de venlafaxina de liberacion prolongada recubiertas.
EP2533766B1 (fr) Mini-comprimés pharmaceutiques à libération prolongée d'acétate de flécaïnide
WO2001080824A2 (fr) Formes de dosage a liberation a modifiee a double mecanisme pour medicaments faiblement doses
US20150366850A1 (en) Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
WO2015063670A1 (fr) Composition orale solide a liberation modifiee comprenant de l'oxcarbazepine ou un sel pharmaceutiquement acceptable de ce compose
US9173845B2 (en) Controlled release pharmaceutical compositions of milnacipran
CA2984235C (fr) Composition pharmaceutique a liberation prolongee contenant de la rivastigmine
WO2022144919A1 (fr) Compositions pharmaceutiques à libération prolongée de riociguat
WO2014174388A1 (fr) Compositions pharmaceutiques à libération modifiée de méthylphénidate ou de ses sels
EP3184101A1 (fr) Composition à libération modifiée de lévodopa et de carbidopa
US20090175934A1 (en) Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
TW201609196A (zh) 控制釋放製劑及其製備方法
US20120082718A1 (en) Morphine Formulations
WO2014167439A1 (fr) Compositions pharmaceutiques à libération modifiée de topiramate ou de sels de celui-ci
AU2017260701A1 (en) Delayed-release tablets of methylphenidate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14718756

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14718756

Country of ref document: EP

Kind code of ref document: A1